Gabriella Fontanini

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Phase 3, Gastrointestinal Oncology, Medicine +8

Relation of neovascularisation to metastasis of non-small-cell lung cancer

Paolo Macchiarini, Gabriella Fontanini, F Squartini et al. · The Lancet · 1992 · 771 citations

Non-small-cell Lung Cancer, Medicine, Neovascularization +5

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Fortunato Ciardiello, Rosa Caputo, Roberto Bianco et al. · PubMed · 2001 · 644 citations

Chemoprevention Strategy, Human Growth, Pathology +17

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

Armida D’Incecco, Mariacarla Andreozzi, Vienna Ludovini et al. · British Journal of Cancer · 2014 · 601 citations · Full text

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

Available Inhibitor, Ret/papillary Thyroid Carcinoma, Nih-ret/ptc3 Cells +17